Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Can’t believe some folks sold on today’s news!

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Feb 02, 2021 11:06am

99 Views

Post# 32446694

RE:RE:RE:RE:RE:RE:Can’t believe some folks sold on today’s news!

CancerSlayer wrote:

CancerSlayer wrote:
Enrique wrote:

"We have to beat the competition by a nice margin to be number one and that IMO should not be too hard given that the present competition single agents is 17%CR for Vicinium, 19%CR for Keytruda, and 24% CR for Adstiladrin. We have the potential to make these look like placebos IMO, however we still need more data and for sure we will be able to tell after the next 11 patients are treated. As long as they are all given proper Optimized treatment. The competition's CR rate decreases at 6 months as ours is increasing which is good to see and let's hope it increases even further as we get more data."

Yep...the single agent response rates are pretty dismal & they set a low bar, which our preliminary data has already overcome....& that's based on our "B game" protocol. Looking forward to finally seeing our "A game" play out with our new US teammates.

And where less is better, we've also beaten the competition in terms of the required number of treatments by a "wide" margin. We currently require ~8-10X fewer treatments, which translates into significant cost savings. The single agents will have a projected annual cost of ~$120,000 to $200,000, & possibly higher based on variations in duration of response. Practically speaking, this should also broaden the gap between us & the competition.

Might as well add that our 8-10X "fewer" treatments could also translate into greater treatment compliance as well as happier patients : )...